These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


282 related items for PubMed ID: 8525771

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Treatment with fludarabine of lymphoid neoplasms with low grade malignity resistant to treatment or in relapse].
    Briones J, Montserrat E, Urbano-Ispizua A, Esteve J, Colomer D, López-Guillermo A, Bosch F, Hadjieu E, Rozman C.
    Med Clin (Barc); 1996 Jun 15; 107(3):86-9. PubMed ID: 8754493
    [Abstract] [Full Text] [Related]

  • 4. Alpha-interferon as maintenance drug after initial fludarabine therapy for patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma.
    Zinzani PL, Levrero MG, Lauria F, Rondelli D, Zaja F, Russo D, Fanin R, De Rossi G, Mauro FR, Bendandi M, Gozzetti A, Dianzani F, Mandelli F, Tura S.
    Haematologica; 1994 Jun 15; 79(1):55-60. PubMed ID: 15378949
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas.
    Bremer K.
    J Cancer Res Clin Oncol; 2002 Nov 15; 128(11):603-9. PubMed ID: 12458340
    [Abstract] [Full Text] [Related]

  • 8. Fludarabine in the treatment of lymphoproliferative malignancies.
    Feldman EJ, Keating MJ.
    Cancer Invest; 1993 Nov 15; 11(3):314-8. PubMed ID: 8485654
    [No Abstract] [Full Text] [Related]

  • 9. Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine.
    Juliusson G, Elmhorn-Rosenborg A, Liliemark J.
    N Engl J Med; 1992 Oct 08; 327(15):1056-61. PubMed ID: 1355853
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Fludarabine for chronic lymphocytic leukemia.
    Erman M, Celik I, Tekuzman G.
    N Engl J Med; 2001 Apr 12; 344(15):1166; author reply 1167-8. PubMed ID: 11302142
    [No Abstract] [Full Text] [Related]

  • 14. Fludarabine increases complete response but not survival compared with conventional alkylator-based regimens for previously untreated chronic lymphocytic leukaemia.
    Richards S.
    Cancer Treat Rev; 2005 Jun 12; 31(4):332-5. PubMed ID: 15894429
    [No Abstract] [Full Text] [Related]

  • 15. Fludarabine in lymphoproliferative malignancies: a single-centre experience.
    Prabhash K, Vikram GS, Nair R, Sengar M, Gujral S, Bakshi A, Gupta S, Parikh PM.
    Natl Med J India; 2008 Jun 12; 21(4):171-4. PubMed ID: 19267037
    [Abstract] [Full Text] [Related]

  • 16. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population.
    Perkins JG, Flynn JM, Howard RS, Byrd JC.
    Cancer; 2002 Apr 01; 94(7):2033-9. PubMed ID: 11932906
    [Abstract] [Full Text] [Related]

  • 17. [Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group].
    Forstpointner R, Hänel A, Repp R, Hermann S, Metzner B, Pott C, Hartmann F, Rothmann F, Böck HP, Wandt H, Unterhalt M, Hiddemann W.
    Dtsch Med Wochenschr; 2002 Oct 25; 127(43):2253-8. PubMed ID: 12397539
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 15.